Page 107 - Read Online
P. 107

Page 12 of 16           Cadamuro et al. Hepatoma Res 2022;8:11  https://dx.doi.org/10.20517/2394-5079.2021.140

               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2022.


               REFERENCES
               1.       Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013;11:13-
                    21.e1; quiz e3.  DOI  PubMed  PMC
               2.       Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383:2168-79.  DOI  PubMed  PMC
               3.       Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev
                    Gastroenterol Hepatol 2020;17:557-88.  DOI  PubMed  PMC
               4.       McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver
                    Int 2006;26:1047-53.  DOI  PubMed
               5.       Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-84.  DOI  PubMed  PMC
               6.       Choi J, Ghoz HM, Peeraphatdit T, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology 2016;64:785-96.  DOI  PubMed
                    PMC
               7.       Zhang H, Zhu B, Zhang H, Liang J, Zeng W. HBV Infection status and the risk of cholangiocarcinoma in Asia: a meta-analysis.
                    Biomed Res Int 2016;2016:3417976.  DOI  PubMed  PMC
               8.       Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a
                    systematic review and meta-analysis. J Hepatol 2020;72:95-103.  DOI  PubMed
               9.       Limpaiboon T, Krissadarak K, Sripa B, et al. Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with
                    poor prognosis. Cancer Letters 2002;181:215-22.  DOI  PubMed
               10.       Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular pathogenesis and targeted therapies for intrahepatic
                    cholangiocarcinoma. Clin Cancer Res 2016;22:291-300.  DOI  PubMed
               11.       Boerner T, Drill E, Pak LM, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology 2021;74:1429-
                    44.  DOI  PubMed  PMC
               12.       Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int
                    2019;39 Suppl 1:63-78.  DOI  PubMed
               13.       Rimassa L, Personeni N, Aghemo A, Lleo A. The immune milieu of cholangiocarcinoma: from molecular pathogenesis to precision
                    medicine. J Autoimmun 2019;100:17-26.  DOI  PubMed
               14.       Lee JI, Campbell JS. Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol 2014;61:432-4.  DOI
                    PubMed
               15.       Cadamuro M, Stecca T, Brivio S, et al. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim
                    Biophys Acta Mol Basis Dis 2018;1864:1435-43.  DOI  PubMed  PMC
               16.       Høgdall D, Lewinska M, Andersen JB. Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. Trends
                    Cancer 2018;4:239-55.  DOI  PubMed
               17.       Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: morpho-molecular pathology, tumor reactive
                    microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87.  DOI  PubMed  PMC
               18.       Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci
                    2014;71:1279-88.  DOI  PubMed  PMC
               19.       Terada T, Kitamura Y, Nakanuma Y. Normal and abnormal development of the human intrahepatic biliary system: a review. Tohoku
                    J Exp Med 1997;181:19-32.  DOI  PubMed
               20.       Brown LF, Berse B, Van de Water L, et al. Expression and distribution of osteopontin in human tissues: widespread association with
                    luminal epithelial surfaces. Mol Biol Cell 1992;3:1169-80.  DOI  PubMed  PMC
               21.       Zeng J, Liu Z, Sun S, et al. Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells.
                    Oncol Lett 2018;15:8681-6.  DOI  PubMed  PMC
               22.       Aishima S, Taguchi K, Terashi T, Matsuura S, Shimada M, Tsuneyoshi M. Tenascin expression at the invasive front is associated
                    with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol 2003;16:1019-27.  DOI  PubMed
               23.       Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor
                    prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013;58:1992-2000.  DOI  PubMed
               24.       Liu Y, Cao L, Chen R, et al. Osteopontin promotes hepatic progenitor cell expansion and tumorigenicity via activation of β-catenin in
   102   103   104   105   106   107   108   109   110   111   112